Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Kiromic BioPharma, Inc. (KRBPQ) had Return on Tangible Equity of 51.56% for the most recently reported fiscal quarter, ending 2024-12-31.
| Income Statement Financials | |
-- |
|
$-8.81M |
|
-- |
|
-- |
|
$5.71M |
|
$-5.71M |
|
$-0.79M |
|
$-6.49M |
|
$-6.49M |
|
$-6.49M |
|
$-6.49M |
|
$-6.49M |
|
$-6.49M |
|
$-5.71M |
|
$-5.14M |
|
1.46M |
|
1.46M |
|
$-0.78 |
|
$-0.78 |
|
| Balance Sheet Financials | |
$3.30M |
|
$4.31M |
|
$5.24M |
|
$8.54M |
|
$20.90M |
|
-- |
|
$0.23M |
|
$21.13M |
|
$-12.59M |
|
$-12.59M |
|
$-12.59M |
|
1.53M |
|
| Cash Flow Statement Financials | |
$-19.46M |
|
$-0.37M |
|
$18.41M |
|
$3.20M |
|
$1.79M |
|
$-1.41M |
|
$0.60M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.16 |
|
-- |
|
-- |
|
-- |
|
-1.08 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-19.82M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
51.56% |
|
|
Return on Tangible Equity |
51.56% |
-75.95% |
|
51.56% |
|
$-8.21 |
|
$-13.57 |
|
$-13.32 |
|